7月31日，多只前期表现强势的创新药ETF有所回调。拉长时间来看，创新药主题ETF仍然是近期全市 场回报率较高的一类ETF产品。Wind数据显示，截至7月31日，来自华泰柏瑞基金、万家基金、汇添富 基金旗下的港股创新药主题ETF今年以来回报率均超过100%。 有业内人士认为，下一阶段创新药领域有望迎来"1-10"的爆发阶段，更多创新药产品在国内上市放量， 同时海外市场会出现代表性新药。相关板块投资正经历从"防御性配置"向"进攻性赛道"的范式转换。但 是，创新药板块的普涨行情不可能持续，后续的超额收益取决于投资者的认知和对信息的解读能力，真 正有创新能力的创新药企才能吸引到资金的青睐。 多只创新药"翻倍基"涌现 医药板块在经过数年的调整之后，今年以来表现不俗。以7月29日的数据为例，创新药板块行情火热， 多只相关主题基金单日净值增长率超4%。Wind数据显示，当日已有6只ETF今年以来涨幅超过100%， 均为创新药主题产品。公开资料显示，这6只ETF来自汇添富基金、华泰柏瑞基金、景顺长城基金、广 发基金、银华基金、万家基金6家公募机构。 在7月30日和7月31日，创新药板块出现分化，部分创新药主题ETF出现一定 ...

Group 1 - The core viewpoint is that the innovative drug sector is experiencing a significant growth phase, with expectations for a "1-10" explosive stage as more innovative drugs are launched domestically and representative new drugs appear in overseas markets [1][3] - Innovative drug ETFs have shown strong performance, with several funds achieving over 100% returns this year, indicating a robust interest in this sector [1][2] - The investment landscape is shifting from defensive to offensive strategies, with innovative drugs being viewed as a growth line that can withstand market cycles [3][4] Group 2 - Fund managers express optimism about the potential for excess returns in the innovative drug sector, anticipating a long harvest period starting from 2025 [3][4] - The innovative drug sector is characterized by high investment, long cycles, and intense competition, which may lead to valuation bubbles if not carefully managed [5][6] - Evaluating innovative drug companies should focus on global competitiveness and domestic commercialization capabilities, with an emphasis on strategic partnerships and market positioning [7]

Core Viewpoint - The article highlights the significant growth in the pharmaceutical sector, particularly in innovative drug funds, with the number of "doubling funds" increasing from 4 to 13 in a short period, indicating strong investor interest and market momentum [1][2]. Group 1: Fund Performance - As of July 31, 2023, 13 public funds have achieved a net value growth rate exceeding 100% this year, with the top performer, 汇添富香港优势精选A, showing a remarkable increase of 143.24% [1]. - Five Hong Kong innovative drug ETFs have also joined the "doubling fund" ranks, reflecting a strong focus on the innovative drug sector by investors [2]. Group 2: Market Trends - The "doubling fund" list indicates that the innovative drug sector is the biggest winner in the capital market this year, with 11 out of 13 funds directly related to "medicine" or "innovative drugs" [3]. - The innovative drug sector has shown high growth in product revenue and licensing deals, with a 23.9% year-on-year increase in licensing transactions and a staggering 383% increase in upfront payments for these deals [3]. Group 3: Investment Insights - Fund managers express optimism about the innovative drug sector's fundamentals, suggesting that the valuation remains reasonable and that returns are expected to be favorable [4]. - The rise of passive index products, particularly ETFs, indicates a shift in market dynamics, with investors increasingly favoring low-cost, transparent investment vehicles during bullish market conditions [5][6]. Group 4: Cautionary Notes - Despite the strong performance of innovative drug funds, there are warnings about potential volatility and risks associated with high returns, as past performance has shown significant drawdowns [7]. - Investment strategies are suggested to focus on sectors with lagging performance, such as A-share innovative drugs and medical devices, to capitalize on potential valuation improvements [8].

Core Viewpoint - The adjustment of the Guozheng Hong Kong Stock Connect Innovative Drug Index aims to enhance its investment value by excluding CXO companies and increasing the frequency of index adjustments, reflecting the latest trends in China's innovative drug industry [1][2]. Group 1: Index Adjustment Details - The sample selection criteria will now focus on companies whose main business involves the research and production of innovative drugs, excluding CXO services [1]. - The index will undergo quarterly adjustments, implemented on the next trading day following the second Friday of March, June, September, and December each year [1]. Group 2: Market Insights - The exclusion of CXO companies is expected to sharpen the index's focus on innovative drug manufacturers, which are seen as industry leaders reflecting the trend of domestic innovative drug companies going global [1][2]. - The innovative drug sector is currently experiencing a growth phase, with any quality innovative drug company potentially attracting capital through product upgrades, thereby boosting market valuations [2]. Group 3: Long-term Outlook - The long-term investment value of innovative drugs is supported by the industry's improving fundamentals, with significant growth in BD transaction amounts expected to continue [3]. - The recognition of R&D capabilities in the innovative drug sector has become a market consensus, indicating a shift from sporadic breakthroughs to a more comprehensive advancement [3]. Group 4: Recent Market Activity - The innovative drug sector has seen a continuous rise, with related ETFs attracting significant capital interest, indicating active trading sentiment [4]. - On July 29, the trading volume for the Silver Hua Fund's innovative drug ETF exceeded 707 million yuan, while the Hong Kong innovative drug ETF reached 2.73 billion yuan, reflecting strong investor engagement [4].

Core Viewpoint - The Hong Kong Stock Connect Innovative Drug ETF (520880) is experiencing significant trading activity and price fluctuations, influenced by expectations of interest rate cuts by the Federal Reserve, with a notable increase in market interest and capital inflow [1][3][9]. Group 1: Market Performance - The Hong Kong Stock Connect Innovative Drug ETF (520880) opened lower but maintained a slight increase of 0.64% during early trading, reflecting ongoing market interest [1]. - The ETF's trading price has shown a significant premium over its net asset value, with a peak increase of over 8% during trading, prompting the fund manager to issue a risk alert regarding market premiums [3]. - The ETF has seen a substantial capital inflow, with 132 million yuan on a single day and a total of 194 million yuan over two days [3]. Group 2: Index Performance - The Hong Kong Stock Connect Innovative Drug ETF passively tracks the Hang Seng Hong Kong Stock Connect Innovative Drug Select Index, which focuses on the innovative drug industry, primarily consisting of R&D companies with high concentration in leading stocks [5]. - As of July 29, the Hang Seng Hong Kong Stock Connect Innovative Drug Select Index has increased by 107.56% year-to-date, significantly outperforming the Hang Seng Index and the Hang Seng Tech Index by 80.32% and 81.23%, respectively [7][8]. Group 3: Industry Outlook - The innovative drug sector is identified as having clear industry trends and growth potential, with current valuations considered attractive, indicating room for foreign investment in Hong Kong's innovative drug market [9]. - Multiple catalysts, including performance growth and international expansion, are expected to support further strength in the innovative drug sector [9].

Group 1 - The innovative drug sector has seen significant performance this year, with multiple funds achieving net value doubling, and the top performer nearing a 140% return, leading to a suspension of new subscriptions [1][3] - As of July 28, the top-performing fund, Huatai-PineBridge Hong Kong Advantage Selected Mixed Fund (QDII), reported a return of 139.12%, attracting substantial inflows [3][4] - Other notable funds include Changcheng Pharmaceutical Industry Selected Mixed Fund with a return of 129.35% and Zhongyin Hong Kong Stock Connect Pharmaceutical Mixed Fund at 119.64% [4] Group 2 - The innovative drug sector remains a focal point for market attention, with strong inflows into various innovative drug-themed ETFs, indicating robust investor interest [7] - On July 30, Huabao Hong Kong Stock Connect Innovative Drug ETF surged nearly 9%, prompting the fund company to issue a risk alert due to high premium rates [7][9] - The trading volume for Huabao Hong Kong Stock Connect Innovative Drug ETF reached 2.502 billion yuan, with a turnover rate of 568.61%, reflecting intense market activity [9] Group 3 - Fund managers highlight the ongoing support from policies, continuous R&D advancements, and accelerated internationalization as key factors for the innovative drug sector's positive outlook [9][10] - Upcoming clinical data and academic conferences, such as the European Society of Cardiology Congress and the European Society for Medical Oncology Congress, are expected to catalyze further developments in the sector [9] - The internationalization of China's innovative drug industry is gaining momentum, with numerous product collaboration agreements with multinational companies, enhancing investor confidence [10]

Group 1 - The core viewpoint of the news highlights the strong performance of innovative drug ETFs in the Hong Kong market, driven by positive market sentiment and favorable industry trends [1][2][3] - The A-share market showed mixed results, with the Shanghai Composite Index up by 0.52% and the Shenzhen Component Index down by 0.06%, indicating a cautious trading environment [1] - The trading volume in the Shanghai and Shenzhen markets reached 1,102.2 billion yuan, a decrease of 43.6 billion yuan compared to the previous day, reflecting reduced investor activity [1] Group 2 - The Hong Kong innovative drug ETF (520880) led the gains with a rise of 6.00%, while the Hong Kong medical ETF (159366) and the Hang Seng Medical ETF (159557) also saw significant increases of 3.85% and 3.01%, respectively [2] - According to Zhongtai Securities, the innovative drug sector remains a clear investment theme with substantial growth potential, suggesting investors should actively embrace this sector [2] - The recent announcement of the 11th batch of drug procurement by the National Organization for Drug Procurement Office emphasizes a trend towards encouraging innovation, with new selection rules favoring innovative drugs [3]

Core Viewpoint - The innovation drug sector has seen a significant surge, with 16 funds achieving a net value growth rate exceeding 100% this year, driven by strong performance in the A-share market and the innovation drug index [1][3]. Fund Performance - As of July 29, 2023, 16 funds have surpassed a 100% net value growth rate, with a notable increase from only 4 such funds by July 28 [1]. - Several funds have also reported net value increases of over 90%, indicating potential for further growth [2]. - The innovation drug sector index rose by 3.23% on July 29, with nearly 20 related stocks hitting the daily limit or increasing by over 10% [3]. Fund Types - The "doubling funds" primarily consist of innovation drug-themed funds, including both active equity funds and ETFs, which have all benefited from the strong performance of the innovation drug sector [3]. - Specific funds such as Huaxin Pharmaceutical Bio A, Nuoan Selected Value A, and others have achieved over 100% growth [3]. Market Dynamics - The current market for innovation drugs is characterized by a high level of activity, with many companies entering a product launch phase after years of research and development [4]. - Factors contributing to the growth include the expiration of patents for multinational corporations, the emergence of Chinese pharmaceutical companies in the innovation drug 2.0 era, and comprehensive policy support [4]. Valuation Insights - As of July 29, the Hong Kong innovation drug index and the Hong Kong Stock Connect innovation drug index have both seen over 111% growth this year, with TTM P/E ratios of 42.63 and 42.02, respectively, indicating reasonable valuation levels compared to historical data [5][6]. - The overall valuation of the innovation drug sector is considered reasonable, with some individual stocks potentially overvalued, but leading companies are still seen as fairly valued [6]. Investment Recommendations - Investment managers suggest a cautious yet optimistic approach to the innovation drug sector, emphasizing the importance of risk and return matching in portfolio allocation [7]. - Recommendations include diversifying investments to mitigate risks, utilizing systematic investment plans to smooth costs, and maintaining a balanced exposure to high-risk sectors [7].

翻倍基金又扎堆出现！ 近期A股市场有点强，7月29日沪指再度登上3600点！创新药板块表现强势，让重点布局这一赛道的权益基金净值走高，涌现出一批"翻倍基"。 此前，汇添富香港优势精选A、长城医药产业精选A、中银港股通医药A、永赢医药创新智选A等四只基金年内业绩已翻倍。 数据显示，截至7月29日，今年以来有16只基金单位净值增长率超过100%，而截至7月28日，"翻倍基"还仅有4只。 此外，还有多只基金年内净值涨幅超过90%，距离翻倍仅差"临门一脚"。 | 今年以来"翻倍基"一览 | | | | | --- | --- | --- | --- | | 今年以来净 | 值增长率 | | | | 证券简称 | (%) | 基金经理(现任) | 投资类型(二级分类) | | 汇添富香港优势精选A | 138.90 | 张萍 | 国际(QDII)混合型基金 | | 长城医药产业精选A | 129.35 | 梁福容 | 偏股混合型基金 | | 中银港股通医药A | 119.64 | 郑宁 | 偏股混合型基金 | | 永赢矢药创新智选A | 114.79 | 储可凡,单林 | 偏股混合型基金 | | 华安医药生物A | 1 ...

【导读】创新药飙了，16只主题基金净值增长率超100%！ 中国基金报记者 方丽 陆慧婧 翻倍基金又 扎堆出现 ！ 近期A股市场有点强，7月29日沪指再度登上3600点！创新药 板块 表现 强势，让重点布局 这一 赛道的权益基金净值走高， 涌现出一批" 翻倍基 " 。 数据显示，截至 7 月 29 日， 今年以来有16只基金单位净值增长率超过100%，而截至7月28日，"翻倍基"还仅有4只。 此外， 还有 多 只基金 年内净值涨幅 超过90%，距离翻倍仅差"临门一脚"。 7月 29 日，创新药概念股强势爆发。当日，A股创新药板块指数涨幅 达到 3 .23 %，近20只相关概念股涨停或涨幅超过10%。 在此 带动 下 ，一批医药主题基金净值大涨，助推年内业绩走高。 主动权益基金方面， 截至7月 29 日， 华安医药生物A、诺安精选价值 A、嘉实互融精选A、中航优选领航A、平安核心优势A 单位净值增长率 均超100 %， 成功跻身"翻倍基"阵营。 此前，汇添富香港优势精选A、长城医药产业精选A 、中银港股通医药A、永赢医药创新智选A等 四 只基金年内业绩已翻倍。 不仅主动权益基金涨势凶猛，指数基金的净值也在飙涨。截 ...